Nanotechnology in Targeted Drugs Delivery System: A New Horizon in Cancer Treatment

Abstract

Cancer treatment is often limited by non-specific toxicity and drug resistance. Nanotechnology offers site -specific, controlled drug delivery using nanoparticles (NPs). This paper highlights types of nanocarries, their mechanism, advantage, limitations, and future prospects in oncology.

Keywords

Introduction

Cancer  = Major global health challenge.

Limitations of conversation chemotherapy : Systemic toxicity , low bioavailability , multi-drug resistance.

Nanotechnology : Emerging tool for precise, targeted therapy.

Aim of Paper : To discuss the role of nanotechnology in targeted cancer therapy.

TYPES OF NANOCARRIERS IN CANCER DRUG DELIVERY

1. Liposomes - biocompatible, approved formulation (e.g., Doxil® for breast/ ovarian cancer).
2. Polymeric nanoparticles - controlled release, biodegradable.
3. Dendrimers - branched polymers, high drug -loading capacity.
4. Gold nanoparticles - drug delivery + photothermal therapy.
5. Magnetic nanoparticles - external magnetic targeting .

MECHANISM OF TARGETED DELIVERY

Passive targeting : Enhanced permeability & retention (EPR) effect in tumor tissues.

Active targeting : Ligand/ receptor binding (e.g., folic acid, antibodies).

Stimuli-responsive systems : pH, temperature, enzymes or light trigger drug release.

ADVANTAGE OF NANOTECHNOLOGY IN CANCER THERAPY.

• Higher drug concentration at tumor site.
• Reduced systemic toxicity .
• Possibility of combining therapy + imaging (theranostics) .
• Controlled & sustained release.

LIMITATIONS/ CHALLENGES.

• High cost of development.
• Stability & scalability issues.
• Potential toxicity of some nanomaterials.
• Regulatory hurdles for clinical approval.

RECENT ADVANCE & EXAMPLES.

• FDA - approved nano formulations

• Doxil® (liposomal doxorubic)
• Abraxane® (albumin-bound paclitaxel).

• Research focus: personalized nanomedicine CRISPR- nanocarrier combination, immune-nanoparticles.

FUTURE PROSPECTIVES

• Integration of AI + nanomedicine for personalized cancer therapy.
• Development of multifunctional nanocarriers (drug + gene + imaging).
• Clinical translation from lab to large-scale production.

CONCLUSION

Nanotechnology holds great promise in targeted cancer therapy.

Although challenges remain , ongoing research & innovation will likely make nanomedicine a mainstay in oncology.

REFERENCES

1. Alexis, F. et Nanoparticle technologies for cancer therapy. Nat Rev Drug Discovery.
2. Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnology .
3. Wang, A Z. et al. Nanoparticle delivery of cancer. Anna Rev Med.
4. FDA database of approved nanomedicine.